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The phosphatidylinositol-3-kinase/Akt pathway has been described to be critical in the
survival of chronic lymphocytic leukemia cells. In this study we analyzed the effect of two
selective chemical inhibitors of Akt (Akti-1/2 and A-443654) on the survival of chronic
lymphocytic leukemia cells.
Design and Methods
Using cytometry we studied the cytotoxic effects of Akt inhibitors on peripheral B and T
lymphocytes from patients with chronic lymphocytic leukemia and from healthy donors.
We studied the changes induced by Akti-1/2 and A-443654 at the mRNA level by perform-
ing reverse transcriptase multiplex ligation–dependent probe amplification. We also stud-
ied the changes induced by both Akt inhibitors in some BCL-2 protein family members on
chronic lymphocytic leukemia cells by western blotting. Moreover, we analyzed the cyto-
toxic effect of Akt inhibitors in patients’ cells with deleted/mutated TP53.
Results
Both inhibitors induced apoptosis in chronic lymphocytic leukemia cells in a dose-depend-
ent manner. Moreover, B cells from patients with chronic lymphocytic leukemia were
more sensitive to Akt inhibitors than T cells from leukemic patients, and B or T cells from
healthy donors. Survival factors for chronic lymphocytic leukemia cells, such as inter-
leukin-4 and stromal cell-derived factor-1α, were not able to block the apoptosis induced
by either Akt inhibitor. Akti-1/2 did not induce any change in the mRNA expression pro-
file of genes involved in apoptosis, while A-443654 induced some changes, including an
increase in NOXA and PUMA mRNA levels, suggesting the existence of additional targets
for A-443654. Both inhibitors induced an increase in PUMA and NOXA protein levels, and
a decrease in MCL-1 protein level. Moreover, Akti-1/2 and A-443654 induced apoptosis
irrespective of TP53 status.
Conclusions
These results demonstrate that Akt inhibitors induce apoptosis of chronic lymphocytic
leukemia cells and might be a new therapeutic option for the treatment of chronic lym-
phocytic leukemia.
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Introduction
The phosphatidylinositol-3-kinase (PI3K) pathway
has been described to be critical in the survival of
chronic lymphocytic leukemia (CLL) cells.1-11 PI3K
phosphorylates the D-3 position of phosphatidylinosi-
tol, phosphatidylinositol 4-phosphate and phos-
phatidylinositol 4,5-diphosphate. The cellular levels of
PI3K products are controlled by the balance between
PI3K activity and the phosphatase activity of PTEN
(phosphatase and tensin homolog deleted on chromo-
some ten).12 Interestingly, PTEN protein is reduced or
not detected in 48% of patients with CLL.13
One of the most important targets of PI3K products
is the serine-threonine kinase Akt, also known as pro-
tein kinase B (PKB).14 Akt resides in the cytosol in a
low-activity conformation, and it is activated through
recruitment to cell membranes by PI3K lipid products
and phosphorylation at Thr308 and Ser473. Once Akt
is activated, it is able to promote cell survival through
phosphorylation and inactivation of key components
in the apoptotic cascade. Akt substrates include the
members of the Forkhead family of transcription fac-
tors15 and glycogen synthase kinase-3 (GSK-3),16 which
are inhibited by Akt. Furthermore, GSK-3 inhibition
induces the up-regulation of the anti-apoptotic protein
MCL-1.16 Activation of the PI3K/Akt pathway in CLL
cells induces the phosphorylation of the Forkhead
family member FoxO3a and GSK-3, and an increase in
MCL-1 protein, while inhibition of PI3K induces a loss
of cell viability, dephosphorylation of FoxO3a and
GSK-3, and a decrease in the level of MCL-1 pro-
tein.3,4,11 Importantly, a stronger activation of Akt path-
way has been related to a higher capacity for cell cycle
progression in CLL cells from patients with progres-
sive disease.17 All together, these studies suggest that
Akt plays a prominent role in the survival of CLL;
however, the effect of selective chemical Akt
inhibitors on the survival of CLL cells has not been
reported yet. 
A-443654 is a potent, ATP competitive and
reversible inhibitor of Akt catalyzed phosphorylation
activity. It is a pan-Akt inhibitor and has equal poten-
cy against Akt1, Akt2 or Akt3.18,19 Together with the
decrease in phosphorylation of Akt targets, a concomi-
tant increase in the phosphorylation of Ser473 and
Thr308 Akt residues has been observed. This increase
is PI3K-dependent, as demonstrated by the fact that
incubating the cells with LY294002 blocks it.20
Recently, it was reported that this inhibitor also
inhibits other protein kinases, albeit with slightly
lower potency, such as PKA, PRK2, MSK1 and
DYRK1A.21 It was also reported that Akti-1/2, an ATP
non-competitive Akt inhibitor, was a highly selective
Akt inhibitor, blocking Akt1 and Akt2 but not Akt3
activity; the pleckstrin homology domain is required
for the activity of this inhibitor.22,23
In this study we examined the effect of these two
Akt inhibitors on CLL cells.
Design and Methods
Patients with chronic lymphocytic leukemia, healthy
donors and cell isolation
Samples from patients with CLL (Table 1) or healthy
donors were studied. CLL was diagnosed according to
standard clinical and laboratory criteria. Blood samples
were obtained from the Hospital de Bellvitge, L’Hospitalet
de Llobregat, Spain. Written informed consent was
obtained from all patients in accordance with the Hospital
de Bellvitge Ethical Committee’s requirements. 
Mononuclear cells from peripheral blood samples
were isolated by centrifugation on a Ficoll-Hypaque
(Seromed, Berlin, Germany) gradient and cryopre-
served in liquid nitrogen in the presence of 10%
dimethyl sulfoxide (Sigma-Aldrich, Steinheim,
Germany), and are referred to as CLL cells throughout
this article. B-cells (CD19+ cells) were purified from
samples from three patients (n. 49, 50 and 51) by using
the RosetteSep Human B Cell Enrichment Cocktail
(StemCell Technologies, Vancouver, Canada). Blood
samples or isolated mononuclear cells were incubated
with RosetteSep Human B Cell Enrichment Cocktail at
50 µL/mL for 20 min prior to centrifugation on a Ficoll-
Hypaque, according to the manufacturer’s protocol.
Immunological and genetic analyses
CD38 and ZAP-70 were determined by flow cytom-
etry in fixed cells with conjugated antibodies (PE clone
HB7, Becton Dickinson, Franklin Lakes, NJ, USA and
Alexa-Fluor 488, Caltag Laboratories, Burlingame, CA,
USA, respectively). CD19 was determined by flow
cytometry with a conjugated antibody [phycoerythrin
(PE)–conjugated anti-CD19; Becton Dickinson]. 
Genomic alterations were detected by fluorescence
in situ hybridization (FISH). Fluorescent-labeled DNA
probes were used in interphase cytogenetic analyses.
Locus-specific probes (LSI P53/Spectrum-Orange, LSI
ATM/Spectrum-Green, LSI 13S319/Spectrum-Orange,
LSI 13q34/SpectrumAqua) were used to determine loss
of these genetic regions within interphase nuclei.
Trisomy 12 was detected in interphase nuclei using a
chromosomal centromere enumeration probe (CEP)
labeled with Spectrum-Green. These five probes are
packaged together in a commercially available kit
(Vysis Chronic Lymphocytic Leukemia Multicolor Kit)
and were used in accordance with the manufacturer’s
specifications. Cells were fixed with fresh fixative
before placement onto slides. The probe mixture was
applied directly to slides. These slides were denaturat-
ed at 74ºC for 2 min and incubated overnight at 37ºC.
Slides were then washed with 0.4 x saline sodium cit-
rate-0.3% nonidet P-40 (NP-40) at 73±1ºC for 2 min
and 2 x saline sodium citrate-0.1% nonidet P-40 at
room temperature for 1 min. 4’6-diamidino-2-
phenylindole (DAPI) II counterstain was applied to the
target area. Slides were stored at 20ºC in the dark. Two
hundred nuclei were analyzed for each probe, using a
NIKON fluorescent microscope. Cut-off levels used
were 5% for CEP 12 and 7% for locus-specific probes.
The karyotype of all samples was determined.
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Table 1. Characteristics of the chronic lymphocytic leukemia patients studied.
Patient Age/Sex WBC Lymphocytes CD19+ CD38+ ZAP70+ Genomic F/T EC50 (µM) EC50 (µM)
(x109/L) (%) (%) (%) (%) alterations Akti-1/2 A-443654
1 75/F 41 78 77 2 ND ND F
2 63/F 71 84 72 28 53 ND F 7.5
3 64/F 100 76 96 87 40 del13q, del17p T
4 72/M 49 96 84 2 0.56 del13q F
5 76/F 27 84 75 15 3 ND F 9 0.75
6 71/M 94 94 88 16 26 normal F 0.7
7 61/M 76 84 82 2 6 ND F 0.6
8 70/M 98 94 86 2 5 del17p F 8 0.6
9 77/F 137 68 90 10 14 normal F 0.45
10 73/F 82 88 80 20 5 ND F 0.65
11 74/F 31 93 89 ND 14 ND F 0.4
12 65/M 16 93 83 91 38 normal F 0.5
13 57/M 31 84 79 50 2 del11q F 0.8
14 61/F 90 96 80 9 5 normal T 12.5 0.65
15 50/M 60 94 80 30 6 del13q T 10 0.85
16 71/F 77 84 86 6 12 normal T 13 0.75
17 66/F 91 95 73 20 28 del13q F 8.5 0.55
18 66/F 44 86 80 4 14 ND T 11 0.75
19 81/F 76 92 85 51 27 ND T 8 0.45
20 70/M 58 94 70 12 10 del13q F 12
21 82/M 67 80 80 78 0.05 ND F 13
22 75/F 93 84 90 4 0,64 del13q F 15
23 85/F 100 80 80 12 22 del13q F 7
24 63/F 56 91 83 13 1,5 normal T 0.4
25 75/M 83 89 82 35 15 del13q F
26 53/M 113 94 94 51 10 del13q T 0.5
27 59/F 89 90 80 7 34 normal F 5 0.75
28 81/F 22 92 72 5 3 ND F 6 0.65
29 86/M 22 89 71 28 42 ND F 0.7
30 69/M 53 87 74 ND ND del13q T 0.5
31 56/M 55 95 72 70 53 del13q, del11q T 12
32 54/M 30 73 48 13 54 ND T 12.5 0.8
33 71/F 54 74 80 9 44 del13q T 10 0.85
34 81/F 31 83 79 7 7 normal T
35 72/M 37 86 74 2 1 normal F
36 74/M 590 97 ND 24 52 tris12 T
37 85/M 31 87 80 30 50 ND F 0.4
38 71/M 48 87 87 18 4 normal F
39 54/M 132 93 88 19 14 normal T 0.5
40 70/M 131 98 86 93 39 del17p, del11q T
41 73/F 18 86 ND 24 29 del17p T 5
42 81/M 24 95 85 60 31 tris12, del11q T
43 66/F 44 86 80 4 14 ND T 12 0.8
44 80/M 96 93 80 2 0.48 del13q, del11q T
45 74/F 43 94 87 10 8 del13q T
46 58/M 74 89 90 24 6 del13q T
47 70/M 79 84 91 ND ND del13q T
48 78/M 85 95 84 ND ND tris12 T
49 64/M 88 95 97 ND 10 del13q F
50 67/F 88 90 96 20 28 del13q F
51 72/M 51 92 97 7 26 ND F
WBC: white blood cell count; F: female; M: male; del: deletion; tris: trisomy and ND: not determined; F: fresh cells;T: frozen-thawed cells.
Reagents
Akti-1/2 (previously known as Akt-I-1/2) was pur-
chased from Calbiochem-Novabiochem (San Diego,
CA, USA), A-443654 was kindly provided by Abbott
(North Chicago, IL, USA), recombinant human inter-
leukin-4 (IL-4) and stromal cell-derived factor-1α (SDF-
1α) were purchased from Immunotools (Friesoythe,
Germany), annexin V–fluorescein isothiocyanate and
propidium iodide were from Bender MedSystems
(Vienna, Austria). Nutlin-3a was provided by
Hoffmann-La Roche. Z-VAD.fmk was purchased from
Bachem (Bubendorf, Switzerland). Ethanol and RNase
A were from Sigma-Aldrich.
Cell culture
Lymphocytes were cultured immediately after thaw-
ing or isolation in RPMI 1640 culture medium supple-
mented with 10% heat-inactivated fetal bovine serum, 2
mM glutamine, 100 U penicillin and 100 ng/mL strepto-
mycin at 37°C in a humidified atmosphere containing
5% CO2. To avoid differences in cell viability due to the
cell concentration, flow cytometry experiments were
performed at a concentration of 1×106 cells/mL, whereas
the concentration used for reverse transcriptase multi-
plex ligation-dependent probe amplification (RT-MLPA)
and the experiments to obtain cell extracts to perform
western blotting was 2.5 to 3×106 cells/mL.
Analysis of apoptosis by flow cytometry
Apoptosis was assessed by exposure of phos-
phatidylserine and membrane integrity. This was
determined by annexin V-fluorescein isothiocyanate
and propidium iodide double staining. Flow cytomet-
ric analysis was performed using FACSCalibur and
CellQuest software (Becton Dickinson), as described
previously.24 Cell viability was measured as the per-
centage of annexin V and propidium iodide double-
negative cells. The results of flow cytometric analysis
of three representative samples are shown in Online
Supplementary Figure S1A. 
To analyze apoptosis in T cells and B cells from the
samples, 5×105 cells were incubated for 24 h with the
indicated factors. Cells were then washed in annexin-
binding buffer, and incubated in 50 µL annexin-binding
buffer with allophycocyanin-conjugated anti-CD3 and
phycoerythrin-conjugated anti-CD19 from Becton
Dickinson, for 10 min in the dark. Cells were then
diluted with annexin-binding buffer to a volume of
150 µL and incubated with 1 µL annexin V-fluorescein
isothiocyanate for 15 min in the dark. Cells were ana-
lyzed using FACSCalibur and CellQuest software.
Results of flow cytometric analysis of one CLL sample
and one sample from a healthy donor are shown in
Online Supplementary Figure S1B.
Apoptosis in T cells and B cells was also assessed by
subdiploid DNA analysis. Briefly, 1×106 cells were har-
vested, washed twice in phosphate-buffered saline
containing 1% fetal bovine serum (PBS/1% FBS) and
fixed in 70% ethanol. The cells were centrifuged,
washed in PBS/1% FBS, and resuspended in 0.5 mL
PBS/1% FBS, containing allophycocyanin–conjugated
anti-CD3 or allophycocyanin–conjugated anti-CD19.
Tubes were incubated for 20 min at room temperature
in the dark and then propidium iodide (50 µg/mL) and
RNase A (100 µg/mL) were added and incubated for 30
min at room temperature in the dark before flow
cytometry analysis to identify the sub-G0 peak corre-
sponding to apoptosis in CD3+ or CD19+ cells. Cells
were analyzed using FACSCalibur and CellQuest soft-
ware.
Western blot analysis
Cells were lysed with Laemmli sample buffer, and
western blotting was performed as described previous-
ly.2 We used antibodies against p53 (Ab-5,
Neomarkers, Fremont, CA, USA), MCL-1 and Akt
(Santa Cruz Biotechnology, Santa Cruz, CA, USA),
BCL-2 (Dako, A/S, Glostrup, Denmark), PUMA and
NOXA (Abcam, Cambridge, UK), P-Ser473-Akt, P-
GSK-3α/β and P-FoxO1/FoxO3a (Cell Signaling
Technologies, Beverly, MA, USA), and β-actin (Sigma-
Aldrich). Antibody binding was detected using a sec-
ondary antibody conjugated to horseradish peroxidase
and an enhanced chemiluminescence detection system
(Amersham, Buckinghamshire, UK). 
Reverse transcriptase multiplex ligation-dependent
probe amplification
RNA was analyzed by RT-MLPA using a SALSA
MLPA KIT R011 Apoptosis mRNA from MRC-Holland
(Amsterdam, The Netherlands) for the simultaneous
detection of 38 mRNA molecules.25 In brief, RNA sam-
ples (200 ng total RNA) were first reverse transcribed
using a gene-specific probe mix. The resulting cDNA
was annealed overnight at 60°C to the MLPA probe
mix. Annealed oligonucleotides were ligated by adding
Ligase-65 (MRC-Holland, Amsterdam, The
Netherlands) and incubated at 54°C for 15 min. Ligation
products were amplified by polymerase chain reaction
(PCR; 35 cycles, 30 s at 95°C; 30 s at 60°C, and 1 min at
72°C) with one unlabeled and one FAM labeled primer.
The final PCR fragments amplified were separated by
capillary electrophoresis on a 48-capillary ABI-Prism
3730 Genetic Analyzer (Applied Biosystems/Hitachi,
Foster City, CA, USA). Peak area and height were meas-
ured using GeneScan analysis software (Applied
Biosystems). The sum of all peak data was set at 100%
to normalize for fluctuations in total signal between
samples, and individual peaks were calculated relative
to the 100% value.
Statistical analysis
Results are shown as the mean ± standard error of
the mean (SEM) of values obtained in independent
experiments. The paired Student’s t test was used to
compare differences between paired samples. Data
were analyzed using the SPSS 14.0 software package
(Chicago, IL, USA).
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Results
Akti-1/2 and A-443654 inhibit Akt in chronic 
lymphocytic leukemia cells
To assess the effect of Akti-1/2 and A-443654 on Akt
activity in CLL cells, we examined the phosphorylation
status of Akt or Akt substrates which are used to assess
the activation status of Akt. Akti-1/2 inhibited Ser473
phosphorylation in a dose-dependent manner (Figure
1A). As previously described for other cell types,18,20 A-
443654 induced an increase in Ser473 phosphorylation.
In order to confirm that A-443654 was inhibiting Akt,
we analyzed the status of the Akt substrates GSK3α/β
and FoxO1/FoxO3a. Both inhibitors reduced the phos-
phorylation of GSK3α/β and FoxO1/FoxO3a (Figure
1B), demonstrating that they inhibited Akt activity.
Akt inhibitors induce apoptosis in chronic
lymphocytic leukemia cells
To examine the ability of Akt inhibitors to induce
apoptosis in CLL cells, we incubated CLL cells with a
range of concentrations of Akti-1/2 (0.5-20 µM) and A-
443654 (0.1-1 µM) for 24 h and measured cell viability.
Both inhibitors induced apoptosis in a dose-dependent
manner (Figure 2A and 2B) and in a time-dependent
manner (Online Supplementary Figure S2). The half-max-
imal effective concentration (EC50) was 9.85±0.67 µM
(range, 5 to 15 µM) for Akti-1/2, and 0.63±0.03 µM
(range, 0.40 to 0.85 µM) for A-443654. Similar results
were obtained in purified CD19+ CLL cells (Online
Supplementary Figure S3). Akti-1/2 and A-443654
induced apoptosis in all the analyzed samples, inde-
pendently of sex, ZAP70 status, CD38 status or genom-
ic alterations (data not shown).
Differential effect of Akt inhibitors on B and T cells
from patients with chronic lymphocytic leukemia 
and healthy donors
Next, we analyzed the sensitivity of normal B and T
cells to Akt inhibitors, in terms of induction of apopto-
sis. The number of apoptotic T cells (CD3+ cells) was
measured in CLL samples and blood samples from
healthy donors exposed to several doses of Akti-1/2
Figure 1. Akti-1/2 and A-443654 effects on the phosphorylation
of Akt and Akt substrates. CLL cells were incubated with or with-
out a range of doses of Akti-1/2 for 2 h. (A) Cells were lysed and
whole extracts were analyzed by western blot as described in the
Design and Methods section. Results from three patients are
shown (n=3). (B) CLL cells were incubated with or without 5 µM
Akti-1/2 and 0.5 µM (patients 2, 4 and 5) or 1 µM (patient 3) A-
443654 for 2 h. Cells were lysed and whole extracts were ana-
lyzed by western blot as described in the Design and Methods sec-
tion. Results from four representative patients are shown (n=9).
Figure 2. Cytotoxic effect of Akt inhibitors on CLL cells and on
peripheral blood lymphocytes (PBL) from healthy donors. Cells
from CLL patients were incubated for 24 h with or without various
doses of Akti-1/2 (A, n=15) and A-443654 (B, n=15). Viability was
measured by analysis of phosphatidylserine exposure and PI
uptake as described in the Design and Methods section. Cells
from CLL patients and healthy donors were incubated for 24 h
with or without various doses of Akti-1/2 (C, n=9 and n=3, respec-
tively) and A-443654 (D, n=13 and n = 8, respectively). Viability
was measured as non-apoptotic CD3+/CD19– T cells from PBL (p)
and CLL (P) or CD3–/CD19+ B cells from PBL (m) and CLL (M) as
described in the Design and Methods section. Viability is
expressed as the percentage of the viability of untreated cells.
Data are shown as the mean value ± SEM. *p<0.005, treated ver-
sus untreated cells (A, B), or B cells versus T cells from patients
with CLL (C, D).
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(up to 10 µM) and A-443654 (up to 1 µM) for 24 h.
Incubation with 5 µM Akti-1/2 reduced the percentage
of viable CLL cells to 64.64±6.12%. In contrast, the
percentage of viable T cells from CLL samples was
102.4±3.46%. Interestingly, B and T cells derived from
healthy donors were resistant to Akti-1/2-induced
apoptosis. Thus, after incubation with 5 µM Akti-1/2
the percentage of viable B cells and T cells were 91.6 ±
2.1% and 100.7±7.2%, respectively (Figure 2C).
Similar results were obtained in the treatment of CLL
cells and cells from healthy donors with A-443654, but
the difference between CLL cells and B or T cells from
healthy donors was less pronounced than in the case
of Akti-1/2. Incubation with 0.5 µM A-443654 reduced
the percentage of viable CLL cells to 64.2±4.9%. In
contrast, the percentage of viable T cells was
91.3±3.7%. Furthermore, B and T cells derived from
healthy donors were less sensitive than cells from CLL
samples to A-443654-induced apoptosis. Thus, after
incubation with 0.5 µM A-443654 the percentages of
viable B and T cells were 83.4±5.8% and 87.1±5.9%,
respectively (Figure 2D). Similar results were obtained
when CLL cells and cells from healthy donors were
treated for 48 h with both Akt inhibitors (Online
Supplementary Figure S4). We confirmed this differen-
tial induction of apoptosis between CLL cells and nor-
mal lymphocytes by performing an analysis of the
DNA content. We observed that CLL cells were more
sensitive than T cells and normal B cells to the Akt
inhibitor-induced increase in sub-G0 peak (Online
Supplementary Figure S5). These results indicate that B
cells from CLL samples are more sensitive than normal
B and T cells to Akt inhibitor-induced apoptosis.
Effect of survival factors in combination 
with Akt inhibitors
We studied the effect of two well-known survival
factors in CLL cells, IL-426 and SDF-1α,27 in combina-
tion with Akt inhibitors. We used selected CLL sam-
ples in which these factors induced a survival effect.
Thus, we treated CLL cells with 10 ng/mL IL-4 (Figure
Akt inhibitors induce apoptosis in CLL cells
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Figure 3. Effect of survival signals on the apoptotic activity of Akt
inhibitors. CLL cells were untreated or treated with 10 ng/mL IL-4
(A, n = 10) or 50 ng/mL SDF-1α (B, n = 7) without (white filled
bars) or with 10 µM Akti-1/2 (gray filled bars) or 0.5 µM A-
443654 (black filled bars) for 48 h. Viability was measured by
analysis of phosphatidylserine exposure and propidium iodide
uptake as described in the Design and Methods section. Data are
shown as the mean value±SEM. **p<0.001 control versus IL-4
and Akt inhibitors treated cells versus control, IL-4 or SDF-1α;
*p<0.01 control versus SDF-1α-treated cells.
Figure 4. Apoptosis-related gene expression profile induced by
Akti-1/2 and A-443654. Cells from CLL patients were untreated
(open bars) or treated with 5 µM Akti-1/2 or 0.5 µM A-443654
(black filled bars) for 24 h. Cells were lysed, and NOXA (A) and
PUMA (B) mRNA expression was analyzed by RT-MLPA as
described in the Design and Methods section. The results are
shown as the mean value ± SEM of four and eight different exper-
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3A) or 50 ng/mL SDF-1α (Figure 3B) and with or with-
out 10 µM Akti-1/2 or 0.5 µM A-443654 for 48 h, and
then measured cell viability. Neither IL-4 nor SDF-1α
was able to inhibit the apoptosis induced by both Akt
inhibitors. These results show that Akt inhibitors can
induce apoptosis in CLL cells even in the presence of
survival signals.
Characterization of Akt inhibitor-induced apoptosis
in chronic lymphocytic leukemia
We investigated the effect of Akt inhibitors on the
overall apoptosis mRNA expression profile by perform-
ing RT-MLPA.25 Treatment of CLL cells with 5 µM
Akti-1/2 for 24 h did not induce any significant change
in the RT-MLPA profile (Figure 4 and Online
Supplementary Figure S6A). The results indicated that
Akt inhibition has minimal effects on the apoptosis
mRNA expression profile. Surprisingly, incubation of
CLL cells with 0.5 µM A-443654 for 24 h induced an
increase in the mRNA levels of NOXA and PUMA and
a decrease in the mRNA levels of BMF, BID, one BAX
probe, BCLw, NAIP, AIF, APAF and APAFL (Figure 4 and
Online Supplementary Figure S6B). Similar results were
obtained in purified CD19+ CLL cells (Online
Supplementary Figure S7). Thus, A-443654-induced
mRNA changes are likely independent of its activity of
inhibiting Akt.
We then investigated the effect of Akt inhibitors on
the expression of BCL-2 family proteins. Western blot
analysis revealed that Akti-1/2 and A-443654 increased
| 1704 | haematologica | 2009; 94(12)
Figure 5. Apoptosis profile induced by Akti-1/2 and A-443654. (A)
Apoptosis-related protein expression profile induced by Akti-1/2
and A-443654. Cells were untreated (ct) or treated with 5 µM Akti-
1/2 (n = 10) and 0.5 µM A-443654 (n = 13) for 24 h, and MCL-1,
NOXA, PUMA, p53 and BCL-2 expression was determined by west-
ern blot. Cell viability is expressed at the top of the figure. β-actin
was used to standardize protein levels. Results from three repre-
sentative patients are shown, two corresponding to Ficoll isolated
cells (patients 7 and 37) and one corresponding to purified CD19+
CLL cells (patient 50). (B) Effect of Z-VAD.fmk on Akti-1/2 and A-
443654-induced MCL-1 decrease. Cells were pretreated with or
without 200 µM Z-VAD.fmk for 30 min and then treated with 5 µM
Akti-1/2 and 0.5 µM A-443654 for 24 h (results from two repre-
sentative patients are shown, n = 3), and MCL-1 levels were deter-
mined by western blot. BCL-2 and β-actin were used to standard-
ize protein levels. Cell viability is expressed at the top of the fig-
ure.
Figure 6. Apoptosis profile induced by Akti-1/2 and A-443654 in
TP53 deleted/mutated samples. (A) Protein expression profile
and cytotoxic effect of Akti-1/2, A-443654 and Nutlin-3a. Cells
were untreated (ct) or treated with 5 µM Akti-1/2, 0.5 µM A-
443654 or 5 µM Nutlin-3a for 24 h, and MCL-1, NOXA and PUMA
expression was determined by western blot. BCL-2 and β-actin
were used to standardize protein levels. Viability was measured by
analysis of phosphatidylserine exposure and propidium iodide
uptake as described in the Design and Methods section. (B)
Apoptosis-related gene expression profile induced by Akti-1/2 and
A-443654 in TP53 deleted/mutated CLL samples. Cells were
untreated or treated with 5 µM Akti-1/2 (white filled bars) or 0.5
µM A-443654 (gray filled bars) and 5 µM Nutlin-3a (black filled
bars) for 24 h. Cells were lysed, and the expression of apoptosis-
related genes was analyzed by RT-MLPA as described in the
Design and Methods section. The results are shown as fold induc-
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NOXA protein levels and decreased MCL-1 protein
levels in all the samples analyzed. PUMA protein lev-
els were also increased in 50% of the samples after
treatment with Akt inhibitors (Figure 5A).
Furthermore, p53 protein was increased by A-443654
but not by Akti-1/2 in all the samples analyzed.
We further analyzed the apoptosis-related protein
expression profile induced by Akti-1/2 and A-443654
at different times. We did not observe any change in
MCL-1, NOXA and PUMA protein levels after 3 h of
treatment with Akt inhibitors (data not shown). NOXA
protein was increased by Akt inhibitors at 6 h while
PUMA protein levels were increased at 12 h.
Moreover, MCL-1 protein was decreased after incuba-
tion with A-443654 for 6 h (Online Supplementary Figure
S8). Finally, pretreatment with 200 µM Z-VAD.fmk for
30 min blocked the decrease in MCL-1 induced by
Akti-1/2 but not that induced by A-443654 (Figure 5B).
These results demonstrate that the decrease in MCL-1
induced by Akti-1/2 is caspase-dependent whereas
that induced by A-443654 is caspase-independent and
precedes the activation of caspases.
Akti-1/2 and A-443654 induce apoptosis 
irrespective of TP53 status in chronic 
lymphocytic leukemia cells
To study the role of p53 in Akti-1/2 and A-443654-
induced apoptosis we analyzed the effect of these
compounds on CLL samples with deleted/mutated
TP53. Patients’ samples with deleted/mutated TP53 or
altered expression have been described previously.28-30
Patient 8 had a 17p deletion in one allele in 43% of
peripheral blood lymphocytes, patient 41 had a 17p
deletion in one allele in 94% of peripheral blood lym-
phocytes, and patient 40 had a frame-shift mutation in
one allele (nucleotide deletion in codon 272) and a 17p
deletion in the other allele in 86% of peripheral blood
lymphocytes. First, we incubated these CLL cells with
5 µM Akti-1/2 or 0.5 µM A-443654 for 24 h.
Interestingly, we observed a decrease in viability in
two of the three samples with Akti-1/2 treatment and
in all three samples with A-443654 treatment (Figure
6A). 
Western blot analysis revealed an increase in NOXA
levels in the three samples when treated with both
inhibitors, while PUMA levels increased in only one
sample (patient 8) with 5 µM Akti-1/2 treatment.
MCL-1 levels decreased with Akti-1/2 in patients 8
and 41, where Akti-1/2 induced apoptosis. In patient
40, MCL-1 levels increased with Akti-1/2 treatment,
and the inhibitor did not induce apoptosis. A-443654
treatment induced a decrease in MCL-1 levels in the
three samples (Figure 6A). As a control of TP53 status
we used 5 µM Nutlin-3a, which has been described to
induce apoptosis and p53 accumulation in cells with
wild-type TP53 but not in those with deleted/mutated
TP53.28
Next, we examined the apoptosis mRNA expression
profile by performing RT-MLPA. Incubation with 5
µM Akti-1/2 or 0.5 µM A-4436545 induced almost the
same mRNA expression profile as that in CLL cells
with the wild-type TP53, except that PUMA mRNA
levels did not increase after treatment with A-443654
(Figure 6B).
Discussion
In this study we investigated the effect of two Akt
inhibitors on the viability of CLL cells. Both Akt
inhibitors induced apoptosis in primary CLL cells.
These results are in agreement with a recent report
describing that introduction of constitutively active
myr.Akt increases the viability of CLL cells.31
The mechanism of action of the two Akt inhibitors
is somewhat different (Online Supplementary Figure S9).
Surprisingly, Akti-1/2 inhibits Akt but does not induce
changes in the RT-MLPA profile. Akt modulates the
transcriptional activity of at least one transcription fac-
tor, FoxO3a,15 which would induce changes in the
mRNA levels of its transcriptional targets BIM32 and
PUMA.33 However, RT-MLPA experiments suggest that
dephosphorylation of FoxO3a induced by Akti-1/2 is
not sufficient to induce the transcription of BIM and
PUMA in CLL cells. As A-443654 is a less specific Akt-
inhibitor,21 the simplest model would be to consider
that inhibition of Akt (common to both inhibitors)
does not induce changes in the RT-MLPA profile, and
that A-443654 has additional targets to explain its
effects on the expression of genes. Thus, A-443654
induces an increase in the levels of p53 protein and the
induction of PUMA mRNA, a transcriptional target of
TP53 in CLL.28,34 In agreement with these data, the
induction of PUMA mRNA by A-443654 was
decreased in CLL cells with deleted/mutated TP53.
Interestingly, Akti-1/2 induced PUMA and NOXA pro-
teins without affecting PUMA and NOXA mRNA. The
mechanism for this effect is unknown and could be
explained by increased translation or decreased prote-
olysis of these proteins. 
A common effect of both Akt inhibitors is the mod-
ulation of NOXA/MCL-1 balance. It has been reported
that in primary CLL cells, the majority of NOXA pro-
tein is associated with MCL-1.35
Thus, Akti-1/2 and A-443654 treatment induced an
increase in NOXA protein levels and a down-regula-
tion of the levels of MCL-1, a critical survival protein
in CLL cells. Furthermore, inhibition of caspases pre-
vents the down-regulation of MCL-1 induced by Akti-
1/2, suggesting that MCL-1 cleavage participates in an
amplification loop that increases cytochrome c release
and apoptosis in CLL cells, as described for PKC
inhibitors.36 In agreement with our results, the intro-
duction of constitutively active myr.Akt increases
MCL-1 protein, and inhibition of MCL-1 by treatment
with siRNA induces apoptosis in CLL.31 The mecha-
nism of regulation of MCL-1 protein by Akt in CLL
cells is unknown. The Akt substrate GSK-3 has been
reported to induce destabilization of MCL-1 protein.16
However, inhibition of GSK-3 does not inhibit the
apoptotic effect of PI3K inhibitors.7 As GSK-3 is inhib-
ited by PKC,37 perhaps the over-expression of active
PKC-βII38 blocks this pathway in CLL cells. 
We found that B cells from CLL samples were more
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sensitive to Akt inhibitors than T cells from CLL sam-
ples, and B or T cells from healthy donors. Chemo-
therapeutic drugs, including fludarabine, chlorambucil,
and doxorubicin induce apoptosis equally in both B
and T cells, leading to immunosuppression.39,40 Thus,
the differential effect of Akti-1/2 and A-443654 in B
and T lymphocytes is of interest. In conclusion, the
results presented here suggest that clinically suitable
small-molecule inhibitors of Akt alone or in combina-
tion with chemotherapeutic drugs might be a new ther-
apeutic option for the treatment of CLL.
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